Amedeo Smart

Free Medical Literature Service

 

Amedeo

Lung Cancer
  Free Subscription

Articles published in
J Clin Oncol
    March 2026
  1. BESSE B, Subbiah V, Curigliano G, Bowles DW, et al
    Final Efficacy and Safety Data From the Phase I/II ARROW Study of Pralsetinib in Patients With Advanced RET Fusion-Positive Non-Small Cell Lung Cancer.
    J Clin Oncol. 2026 Mar 26:JCO2501489. doi: 10.1200/JCO-25-01489.
    >> Share

  2. SCHERPEREEL A, Baas P, Nowak AK, Tsao AS, et al
    Five-Year Clinical Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Unresectable Pleural Mesothelioma in CheckMate 743.
    J Clin Oncol. 2026;44:742-749.
    >> Share

  3. ZHOU H, Zhao H, Hou X, Wang Y, et al
    Izalontamab Brengitecan in Locally Advanced or Metastatic Non-Small Cell Lung Cancer With Actionable Genomic Alterations Outside of Classical EGFR Mutations: A Phase Ib Study.
    J Clin Oncol. 2026 Mar 4:JCO2501929. doi: 10.1200/JCO-25-01929.
    >> Share

    February 2026
  4. ZHAO J, Graetz I, Howard D, Han X, et al
    Medicaid Expansion and Stage at Diagnosis, Timely Initiation and Receipt of Guideline-Concordant Treatment, and Survival Among People With Non-Small Cell Lung Cancer.
    J Clin Oncol. 2026 Feb 13:JCO2501892. doi: 10.1200/JCO-25-01892.
    >> Share

  5. REMON J, Cascone T, Peters S
    Erratum: BR.31 Trial: Adjuvant Durvalumab as the Third Contender in Resected Non-Small Cell Lung Cancer.
    J Clin Oncol. 2026 Feb 6:JCO2600221. doi: 10.1200/JCO-26-00221.
    >> Share

  6. REUSS JE, Bazhenova L, Ismaila N, Abu Rous F, et al
    Therapy for Stage IV Non-Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, 2026.3.0.
    J Clin Oncol. 2026 Feb 3:JCO2502825. doi: 10.1200/JCO-25-02825.
    >> Share

  7. PURI S, Leighl NB, Ismaila N, Rous FA, et al
    Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, 2026.3.0.
    J Clin Oncol. 2026 Feb 3:JCO2502822. doi: 10.1200/JCO-25-02822.
    >> Share

    January 2026
  8. WERMKE M, Gambardella V, Kuboki Y, Felip E, et al
    Reply to: Delta-Like Ligand 3 Expression Across Lung Neuroendocrine Subtypes: Interpreting Response in Small Cell Lung Cancer and Beyond.
    J Clin Oncol. 2026 Jan 22:JCO2502654. doi: 10.1200/JCO-25-02654.
    >> Share

  9. CHEN Y, Liu L, Ming Y, Chen L, et al
    Delta-Like Ligand 3 Expression Across Lung Neuroendocrine Subtypes: Interpreting Response in Small Cell Lung Cancer and Beyond.
    J Clin Oncol. 2026 Jan 22:JCO2501894. doi: 10.1200/JCO-25-01894.
    >> Share

  10. REMON J, Cascone T, Peters S
    BR.31 Trial: Adjuvant Durvalumab as the Third Contender in Resected Non-Small Cell Lung Cancer.
    J Clin Oncol. 2026 Jan 22:JCO2502696. doi: 10.1200/JCO-25-02696.
    >> Share

  11. RUSTHOVEN CG, Serizawa T, Yamamoto M
    Radiosurgery for Small Cell Lung Cancer Brain Metastases: Comparing the JLGK0901 and BWH/DFCI Trials.
    J Clin Oncol. 2026 Jan 20:JCO2501794. doi: 10.1200/JCO-25-01794.
    >> Share

  12. NOGUCHI M, Nimura K, Koide Y
    Expanding Indications for Stereotactic Radiosurgery in Small Cell Lung Cancer With Brain Metastases.
    J Clin Oncol. 2026 Jan 20:JCO2501867. doi: 10.1200/JCO-25-01867.
    >> Share

  13. AKDOGAN O, Canaslan K, Hamitoglu B, Yazici O, et al
    Limitations in Study Design and Stratification in Phase II Stereotactic Radiosurgery Trial for Small Cell Lung Cancer Brain Metastases.
    J Clin Oncol. 2026 Jan 20:JCO2501729. doi: 10.1200/JCO-25-01729.
    >> Share

  14. AIZER AA, Catalano PJ, Rahman R
    Reply to: "Limitations in Study Design and Stratification in Phase II Stereotactic Radiosurgery Trial for Small Cell Lung Cancer Brain Metastases," "Radiosurgery for Small Cell Lung Cancer Brain Metastases: Comparing the JLGK0901 and BWH/DFCI Trials,"
    J Clin Oncol. 2026 Jan 20:JCO2502528. doi: 10.1200/JCO-25-02528.
    >> Share

  15. KEANE FK, Schoenfeld AJ
    Timing Is of the Essence: Sequencing Immune Checkpoint Blockade and Radiotherapy for Success in Lung Cancer.
    J Clin Oncol. 2026 Jan 14:JCO2502726. doi: 10.1200/JCO-25-02726.
    >> Share

  16. GOSS GD, Darling GE, Westeel V, Nakagawa K, et al
    Adjuvant Durvalumab in Completely Resected Early-Stage Non-Small Cell Lung Cancer.
    J Clin Oncol. 2026 Jan 13:JCO2501828. doi: 10.1200/JCO-25-01828.
    >> Share

  17. HIGGINS KA, Hu C, Ross HJ, Jabbour SK, et al
    Chemoradiation +/- Atezolizumab in Limited-Stage Small Cell Lung Cancer: Results of NRG Oncology/Alliance LU005.
    J Clin Oncol. 2026 Jan 13:JCO2501569. doi: 10.1200/JCO-25-01569.
    >> Share

  18. BRADLEY JD, Sugawara S, Lee KH, Ostoros G, et al
    Erratum: Simultaneous Durvalumab and Platinum-Based Chemoradiotherapy in Unresectable Stage III Non-Small Cell Lung Cancer: The Phase III PACIFIC-2 Study.
    J Clin Oncol. 2026 Jan 7:JCO2503012. doi: 10.1200/JCO-25-03012.
    >> Share

    December 2025
  19. DIX DB, Khanna G, Renfro LA, Tfirn IC, et al
    Impact of Pulmonary Tumor Burden in Favorable Histology Wilms Tumor Outcomes: A Report From the Children's Oncology Group Study AREN0533.
    J Clin Oncol. 2025;43:3822-3832.
    >> Share

  20. PIOTROWSKA Z, Yu HA
    Reply to: Blind Spots in REZILIENT-1: Does Post-platinum Zipalertinib Address Needs in Epidermal Growth Factor Receptor ex20ins+ Non-Small Cell Lung Cancer?
    J Clin Oncol. 2025 Dec 17:JCO2502185. doi: 10.1200/JCO-25-02185.
    >> Share

  21. YAO W, Zhou Q, Shi T, Xu L, et al
    Blind Spots in REZILIENT-1: Does Post-Platinum Zipalertinib Address Needs in Epidermal Growth Factor Receptor ex20ins+ Non-Small Cell Lung Cancer?
    J Clin Oncol. 2025 Dec 17:JCO2501501. doi: 10.1200/JCO-25-01501.
    >> Share

  22. FELIP E, Wakelee HA, Fu C, Deng Y, et al
    Reply to: "Improving the Reporting of Long-Term Effects in the IMpower010 Trial" and "Adjuvant Atezolizumab in Early-Stage Non-Small Cell Lung Cancer: Signals, Silences, and the Need for Methodological Clarity".
    J Clin Oncol. 2025 Dec 10:JCO2502102. doi: 10.1200/JCO-25-02102.
    >> Share

  23. HE J, Zheng B, Wang Z
    Adjuvant Atezolizumab in Early-Stage Non-Small Cell Lung Cancer: Signals, Silences, and the Need for Methodological Clarity.
    J Clin Oncol. 2025 Dec 10:JCO2501540. doi: 10.1200/JCO-25-01540.
    >> Share

  24. TOMASINI P, Wang Y, Li Y, Felip E, et al
    Amivantamab Plus Lazertinib in Atypical EGFR-Mutated Advanced Non-Small Cell Lung Cancer: Results From CHRYSALIS-2.
    J Clin Oncol. 2025 Dec 1:JCO2402835. doi: 10.1200/JCO-24-02835.
    >> Share

    October 2025
  25. LIN JK, Niu J, Giordano SH, Li P, et al
    Racial and Ethnic Disparities Along the Treatment Cascade Among Medicare Fee-for-Service Beneficiaries With Metastatic Breast, Colorectal, Lung, and Prostate Cancers.
    J Clin Oncol. 2025;43:3254-3265.
    >> Share

  26. JOHNSON ML, Smit EF, Felip E, Ramalingam SS, et al
    Updated Overall Survival Analysis From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic Non-Small Cell Lung Cancer.
    J Clin Oncol. 2025 Oct 19:101200JCO2502023. doi: 10.1200/JCO-25-02023.
    >> Share

  27. RUDIN CM, Johnson ML, Paz-Ares L, Nishio M, et al
    Ifinatamab Deruxtecan in Patients With Extensive-Stage Small-Cell Lung Cancer: Primary Analysis of the Phase 2 IDeate-Lung01 Trial.
    J Clin Oncol. 2025 Oct 14:101200JCO2502142. doi: 10.1200/JCO-25-02142.
    >> Share

  28. BRADLEY JD, Sugawara S, Lee KH, Ostoros G, et al
    Simultaneous Durvalumab and Platinum-Based Chemoradiotherapy in Unresectable Stage III Non-Small Cell Lung Cancer: The Phase III PACIFIC-2 Study.
    J Clin Oncol. 2025 Oct 13:JCO2500036. doi: 10.1200/JCO-25-00036.
    >> Share

  29. ZHANG Y, Qian B, Song Q, Ma J, et al
    Phase III Study of Mediastinal Lymph Node Dissection for Ground Glass Opacity-Dominant Lung Adenocarcinoma.
    J Clin Oncol. 2025;43:3081-3089.
    >> Share

    September 2025
  30. CHAUNZWA TL, Jabbour SK, Pike LRG, Cooper AJ, et al
    Bridging the Gap: The Evolving Landscape of CNS Management in Small Cell Lung Cancer: Prophylactic Cranial Irradiation in the Modern Era.
    J Clin Oncol. 2025 Sep 26:JCO2501817. doi: 10.1200/JCO-25-01817.
    >> Share

  31. YANG JC, Wang M, Doucet L, Fan Y, et al
    Phase II Dose-Randomized Study of Sunvozertinib in Platinum-Pretreated Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor Exon 20 Insertion Mutations (WU-KONG1B).
    J Clin Oncol. 2025 Sep 9:JCO2500788. doi: 10.1200/JCO-25-00788.
    >> Share

    August 2025
  32. WANG Z, Zhu X
    Taletrectinib in ROS1 Fusion-Positive Non-Small Cell Lung Cancer: Promising Yet Premature?
    J Clin Oncol. 2025 Aug 21:JCO2501055. doi: 10.1200/JCO-25-01055.
    >> Share

  33. PEROL M, Li W, Lai RK, Zhou C, et al
    Reply to: "Baseline Brain Metastasis Imbalance in TRUST: Implications for Interpreting Intracranial Efficacy of Taletrectinib" and "Taletrectinib in ROS1 Fusion-Positive Non-Small Cell Lung Cancer: Promising Yet Premature?".
    J Clin Oncol. 2025 Aug 21:JCO2501448. doi: 10.1200/JCO-25-01448.
    >> Share

  34. COOPER BT, Kondziolka D
    Modern Targeted Radiation in Patients With Brain Metastases From Small Cell Lung Cancer.
    J Clin Oncol. 2025 Aug 12:JCO2501259. doi: 10.1200/JCO-25-01259.
    >> Share

  35. GONDI V, Pugh SL, Mehta MP, Wefel JS, et al
    Hippocampal Avoidance During Prophylactic Cranial Irradiation for Patients With Small Cell Lung Cancer: Randomized Phase II/III Trial NRG-CC003.
    J Clin Oncol. 2025 Aug 11:JCO2500221. doi: 10.1200/JCO-25-00221.
    >> Share

    July 2025
  36. WERMKE M, Gambardella V, Kuboki Y, Felip E, et al
    Phase I Dose-Escalation Results for the Delta-Like Ligand 3/CD3 IgG-Like T-Cell Engager Obrixtamig (BI 764532) in Patients With Delta-Like Ligand 3+ Small Cell Lung Cancer or Neuroendocrine Carcinomas.
    J Clin Oncol. 2025 Jul 24:JCO2500363. doi: 10.1200/JCO-25-00363.
    >> Share

  37. OWEN DH, Halmos B, Puri S, Qin A, et al
    Therapy for Stage IV Non-Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, Version 2025.1.
    J Clin Oncol. 2025 Jul 17:JCO2501062. doi: 10.1200/JCO-25-01062.
    >> Share

  38. REUSS JE, Kuruvilla S, Ismaila N, Azar IH, et al
    Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2025.1.
    J Clin Oncol. 2025 Jul 17:JCO2501061. doi: 10.1200/JCO-25-01061.
    >> Share

  39. AIZER AA, Tanguturi SK, Shi DD, Catalano PJ, et al
    Stereotactic Radiosurgery in Patients With Small Cell Lung Cancer and 1-10 Brain Metastases: A Multi-Institutional, Phase II, Prospective Clinical Trial.
    J Clin Oncol. 2025 Jul 11:JCO2500056. doi: 10.1200/JCO-25-00056.
    >> Share

  40. WU Y, Bi N
    Erratum: Mid-Treatment Positron Emission Tomography-Adaptive Radiotherapy in Stage III Non-Small Cell Lung Cancer: Another Attempt Toward Personalized Care.
    J Clin Oncol. 2025 Jul 10:JCO2501544. doi: 10.1200/JCO-25-01544.
    >> Share

  41. SACHER AG, Miller WH Jr, Patel MR, Paz-Ares L, et al
    Single-Agent Divarasib in Patients With KRAS G12C-Positive Non-Small Cell Lung Cancer: Long-Term Follow-Up of a Phase I Study.
    J Clin Oncol. 2025 Jul 9:JCO2500040. doi: 10.1200/JCO-25-00040.
    >> Share

    June 2025
  42. STEUER CE, Hayashi H, Su WC, Nishio M, et al
    Patritumab Deruxtecan (HER3-DXd; MK-1022) in Non-Small Cell Lung Cancer After Platinum-Based Chemotherapy and Immunotherapy.
    J Clin Oncol. 2025 Jun 24:JCO2402744. doi: 10.1200/JCO-24-02744.
    >> Share

  43. HE J, Tsuboi M, Weder W, Chen KN, et al
    Neoadjuvant Osimertinib for Resectable EGFR-Mutated Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2025 Jun 2:101200JCO2500883. doi: 10.1200/JCO-25-00883.
    >> Share

  44. PIOTROWSKA Z, Passaro A, Nguyen D, Ruiter G, et al
    Zipalertinib in Patients With Epidermal Growth Factor Receptor Exon 20 Insertion-Positive Non-Small Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy With or Without Amivantamab.
    J Clin Oncol. 2025 Jun 1:JCO2500763. doi: 10.1200/JCO-25-00763.
    >> Share

    May 2025
  45. FELIP E, Altorki N, Zhou C, Vallieres E, et al
    Five-Year Survival Outcomes With Atezolizumab After Chemotherapy in Resected Stage IB-IIIA Non-Small Cell Lung Cancer (IMpower010): An Open-Label, Randomized, Phase III Trial.
    J Clin Oncol. 2025 May 30:JCO2401681. doi: 10.1200/JCO-24-01681.
    >> Share

  46. HUANG DD, Yang JC
    Erratum: Every Patient Is Unique and Deserves the Best: The Present and Future Treatment Landscape of Uncommon Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer.
    J Clin Oncol. 2025 May 8:JCO2500997. doi: 10.1200/JCO-25-00997.
    >> Share

    April 2025
  47. DEREK DE-RUI H, Yang JC
    Every Patient Is Unique and Deserves the Best: The Present and Future Treatment Landscape of Uncommon Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer.
    J Clin Oncol. 2025 Apr 25:JCO2500625. doi: 10.1200/JCO-25-00625.
    >> Share

  48. SCHYTTE T, Knap MM, Kristiansen C, Appelt AL, et al
    Toxicity Within 6 Months of Heterogeneous Fluorodeoxyglucose-Guided Radiotherapy Dose Escalation for Locally Advanced Non-Small Cell Lung Cancer in the Scandinavian Randomized Phase III NARLAL2 Trial.
    J Clin Oncol. 2025 Apr 18:JCO2401386. doi: 10.1200/JCO-24-01386.
    >> Share

  49. MIURA S, Tanaka H, Misumi T, Yoshioka H, et al
    Pragmatic Randomized Study of Afatinib Versus Chemotherapy for Patients With Non-Small Cell Lung Cancer With Uncommon Epidermal Growth Factor Receptor Mutations: ACHILLES/TORG1834.
    J Clin Oncol. 2025 Apr 16:JCO2402007. doi: 10.1200/JCO-24-02007.
    >> Share

  50. PEROL M, Li W, Pennell NA, Liu G, et al
    Taletrectinib in ROS1+ Non-Small Cell Lung Cancer: TRUST.
    J Clin Oncol. 2025 Apr 3:JCO2500275. doi: 10.1200/JCO-25-00275.
    >> Share

    March 2025
  51. THAWANI R, Bestvina CM, Vokes EE, Juloori A, et al
    Rationale for Investigation of Neoadjuvant Chemoimmunotherapy Before Chemoradiation in Unresectable Stage III Non-Small Cell Lung Cancer.
    J Clin Oncol. 2025 Mar 27:JCO2402355. doi: 10.1200/JCO-24-02355.
    >> Share

  52. WU Y, Bi N
    Mid-Treatment Positron Emission Tomography-Adaptive Radiotherapy in Stage III Non-Small Cell Lung Cancer: Another Attempt Toward Personalized Care.
    J Clin Oncol. 2025 Mar 21:JCO2402532. doi: 10.1200/JCO-24-02532.
    >> Share

  53. KONG FS, Hu C, Bradley JD, Machtay M, et al
    Reply to: Mid-Treatment Positron Emission Tomography-Adaptive Radiotherapy in Stage III Non-Small Cell Lung Cancer: Another Attempt Toward Personalized Care.
    J Clin Oncol. 2025 Mar 21:JCO2500069. doi: 10.1200/JCO-25-00069.
    >> Share

  54. KINDLER HL, Ismaila N, Bazhenova L, Chu Q, et al
    Treatment of Pleural Mesothelioma: ASCO Guideline Update.
    J Clin Oncol. 2025;43:1006-1038.
    >> Share

  55. SUN L, Marmarelis ME, Aggarwal C
    Management of Patients With EGFR Exon 20-Mutant Advanced Non-Small Cell Lung Cancer.
    J Clin Oncol. 2025 Mar 7:JCO2402624. doi: 10.1200/JCO-24-02624.
    >> Share

    February 2025
  56. OWEN DH, Ismaila N, Ahluwalia A, Feldman J, et al
    Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2024.3.
    J Clin Oncol. 2025 Feb 27:JCO2402785. doi: 10.1200/JCO-24-02785.
    >> Share

  57. LEIGHL NB, Ismaila N, Durm G, Florez N, et al
    Therapy for Stage IV Non-Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, Version 2024.3.
    J Clin Oncol. 2025 Feb 27:JCO2402786. doi: 10.1200/JCO-24-02786.
    >> Share

  58. GAUTSCHI O, Park K, Solomon BJ, Tomasini P, et al
    Selpercatinib in RET Fusion-Positive Non-Small Cell Lung Cancer: Final Safety and Efficacy, Including Overall Survival, From the LIBRETTO-001 Phase I/II Trial.
    J Clin Oncol. 2025 Feb 21:JCO2402076. doi: 10.1200/JCO-24-02076.
    >> Share

  59. PIOTROWSKA Z
    Making Progress Along the Challenging Road of Drug Development for Patients With EGFR Exon 20 Insertion-Positive Non-Small Cell Lung Cancer.
    J Clin Oncol. 2025 Feb 5:JCO2402656. doi: 10.1200/JCO-24-02656.
    >> Share

    January 2025
  60. JANNE PA, Wang BC, Cho BC, Zhao J, et al
    First-Line Mobocertinib Versus Platinum-Based Chemotherapy in Patients With EGFR Exon 20 Insertion-Positive Metastatic Non-Small Cell Lung Cancer in the Phase III EXCLAIM-2 Trial.
    J Clin Oncol. 2025 Jan 29:JCO2401269. doi: 10.1200/JCO-24-01269.
    >> Share

  61. REMON J, Bortolot M, Bironzo P, Cortiula F, et al
    De-Escalation Strategies With Immune Checkpoint Blockers in Non-Small Cell Lung Cancer: Do We Already Have Enough Evidence?
    J Clin Oncol. 2025 Jan 21:JCO2402347. doi: 10.1200/JCO-24-02347.
    >> Share

  62. WERR L, Bartenhagen C, Rosswog C, Cartolano M, et al
    TERT Expression and Clinical Outcome in Pulmonary Carcinoids.
    J Clin Oncol. 2025;43:214-225.
    >> Share

  63. AWAD MM, Forde PM, Girard N, Spicer J, et al
    Neoadjuvant Nivolumab Plus Ipilimumab Versus Chemotherapy in Resectable Lung Cancer.
    J Clin Oncol. 2025 Jan 8:JCO2402239. doi: 10.1200/JCO-24-02239.
    >> Share

  64. PARK CJ, Lee ATM, Ou SI
    ALK Tyrosine Kinase Inhibitors Induced Weight Gain: More Refined Definition of Weight Gain, Glucagon-Like Peptide-1 Agonist Treatment, and Therapeutic Drug Monitoring of ALK+ Non-Small Cell Lung Cancer?
    J Clin Oncol. 2025 Jan 7:JCO2402514. doi: 10.1200/JCO-24-02514.
    >> Share

  65. SANDS J, Ahn MJ, Lisberg A, Cho BC, et al
    Datopotamab Deruxtecan in Advanced or Metastatic Non-Small Cell Lung Cancer With Actionable Genomic Alterations: Results From the Phase II TROPION-Lung05 Study.
    J Clin Oncol. 2025 Jan 6:JCO2401349. doi: 10.1200/JCO-24-01349.
    >> Share

    December 2024

  66. Erratum: Systemic Therapy for Small Cell Lung Cancer: ASCO Guideline Rapid Recommendation Update.
    J Clin Oncol. 2024 Dec 20:JCO2402719. doi: 10.1200/JCO-24-02719.
    >> Share

  67. LUO LY, Xue W, Qumseya A, Vasquez JC, et al
    Whole Lung Irradiation in Rhabdomyosarcoma With Lung Metastases: A Report From the Soft Tissue Sarcoma Committee of the Children's Oncology Group.
    J Clin Oncol. 2024;42:4263-4270.
    >> Share

  68. SIKKEMA BJ, Baart SJ, Paats MS, Smit EF, et al
    Body Weight Gain Associated With Alectinib in Patients With ALK+ Non-Small Cell Lung Cancer: Pooled Analysis of Individual Patient Data From Four Prospective Clinical Trials.
    J Clin Oncol. 2024 Dec 11:JCO2401579. doi: 10.1200/JCO-24-01579.
    >> Share

    November 2024
  69. KALEMKERIAN GP, Khurshid H, Ismaila N
    Systemic Therapy for Small Cell Lung Cancer: ASCO Guideline Rapid Recommendation Update.
    J Clin Oncol. 2024 Nov 20:JCO2402245. doi: 10.1200/JCO-24-02245.
    >> Share

  70. NOGUCHI M, Shindo Y, Wakabayashi K, Koide Y, et al
    Significance of Up-Front Stereotactic Radiosurgery for Non-Small Cell Lung Cancer Patients With Brain Metastases in the Era of New Generation Tyrosine Kinase Inhibitors.
    J Clin Oncol. 2024 Nov 15:JCO2401876. doi: 10.1200/JCO-24-01876.
    >> Share

  71. RUSTHOVEN CG, Miao E, Boe LA, Pike LRG, et al
    Reply to: Significance of Up-Front Stereotactic Radiosurgery for Non-Small Cell Lung Cancer Patients With Brain Metastases in the Era of New Generation Tyrosine Kinase Inhibitors.
    J Clin Oncol. 2024 Nov 15:JCO2402129. doi: 10.1200/JCO-24-02129.
    >> Share


  72. Erratum: Clonal MET Amplification as a Determinant of Tyrosine Kinase Inhibitor Resistance in Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2024 Nov 12:JCO2402413. doi: 10.1200/JCO-24-02413.
    >> Share

  73. BAZHENOVA L, Ismaila N, Abu Rous F, Alluri K, et al
    Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2024.2.
    J Clin Oncol. 2024 Nov 12:JCO2402133. doi: 10.1200/JCO-24-02133.
    >> Share

    October 2024
  74. LEIGHL NB, Akamatsu H, Lim SM, Cheng Y, et al
    Subcutaneous Versus Intravenous Amivantamab, Both in Combination With Lazertinib, in Refractory Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer: Primary Results From the Phase III PALOMA-3 Study.
    J Clin Oncol. 2024;42:3593-3605.
    >> Share

  75. KENMOTSU H
    Combination of Osimertinib and Vascular Endothelial Growth Factor Receptor Inhibitors for EGFR-Mutated Non-Small Cell Lung Cancer: Old or New Regimen?
    J Clin Oncol. 2024 Oct 11:JCO2401921. doi: 10.1200/JCO-24-01921.
    >> Share

  76. LE X, Patel JD, Shum E, Baik C, et al
    A Multicenter Open-Label Randomized Phase II Study of Osimertinib With and Without Ramucirumab in Tyrosine Kinase Inhibitor-Naive EGFR-Mutant Metastatic Non-Small Cell Lung Cancer (RAMOSE trial).
    J Clin Oncol. 2024 Oct 8:JCO2400533. doi: 10.1200/JCO.24.00533.
    >> Share

  77. SUN H, Li M, Huang W, Zhang J, et al
    Thoracic Radiotherapy Improves the Survival in Patients With EGFR-Mutated Oligo-Organ Metastatic Non-Small Cell Lung Cancer Treated With Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors: A Multicenter, Randomized, Controlled, Phase III Tria
    J Clin Oncol. 2024 Oct 7:JCO2302075. doi: 10.1200/JCO.23.02075.
    >> Share

  78. OWEN D, Chapman CH
    Can We Offset Local Recurrence in Locally Advanced Non-Small Cell Lung Cancer? The Merry-Go-Round of Radiation Dose Escalation and Stubborn Outcomes.
    J Clin Oncol. 2024 Oct 4:JCO2401448. doi: 10.1200/JCO-24-01448.
    >> Share

  79. KONG FS, Hu C, Pryma DA, Duan F, et al
    Primary Results of NRG-RTOG1106/ECOG-ACRIN 6697: A Randomized Phase II Trial of Individualized Adaptive (chemo)Radiotherapy Using Midtreatment (18)F-Fluorodeoxyglucose Position Emission Tomography/Computed Tomography in Stage III Non-Small Cell Lung C
    J Clin Oncol. 2024 Oct 4:JCO2400022. doi: 10.1200/JCO.24.00022.
    >> Share

  80. COOPER AJ, Riely GJ
    Can We Find a Place for Trophoblast Cell Surface Antigen 2-Targeted Antibody-Drug Conjugates in Lung Cancer?
    J Clin Oncol. 2024 Oct 1:JCO2401900. doi: 10.1200/JCO-24-01900.
    >> Share

    September 2024

  81. Erratum: Trastuzumab Deruxtecan in Patients With HER2-Mutant Metastatic Non-Small-Cell Lung Cancer: Primary Results From the Randomized, Phase II DESTINY-Lung02 Trial.
    J Clin Oncol. 2024 Sep 13:JCO2401883. doi: 10.1200/JCO-24-01883.
    >> Share

  82. AHN MJ, Tanaka K, Paz-Ares L, Cornelissen R, et al
    Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer: The Randomized, Open-Label Phase III TROPION-Lung01 Study.
    J Clin Oncol. 2024 Sep 9:JCO2401544. doi: 10.1200/JCO-24-01544.
    >> Share

  83. LOVLY CM
    New Benchmark for Targeted Therapies in Lung Cancer: Median Progression-Free Survival for Lorlatinib in Advanced ALK+ Non-Small Cell Lung Cancer Surpasses 5 years.
    J Clin Oncol. 2024 Sep 4:JCO2401147. doi: 10.1200/JCO.24.01147.
    >> Share

  84. CAMIDGE DR, Bar J, Horinouchi H, Goldman J, et al
    Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met Protein-Overexpressing Advanced Nonsquamous EGFR-Wildtype Non-Small Cell Lung Cancer in the Phase II LUMINOSITY Trial.
    J Clin Oncol. 2024;42:3000-3011.
    >> Share

    August 2024
  85. DOWLATI A, Hummel HD, Champiat S, Olmedo ME, et al
    Sustained Clinical Benefit and Intracranial Activity of Tarlatamab in Previously Treated Small Cell Lung Cancer: DeLLphi-300 Trial Update.
    J Clin Oncol. 2024 Aug 29:JCO2400553. doi: 10.1200/JCO.24.00553.
    >> Share

  86. KETPUEAK T, Tan DSW, Popat S
    Immunotherapy in EGFR-Mutant Non-Small Cell Lung Cancer: End of the Road or the First Chapter?
    J Clin Oncol. 2024 Aug 26:JCO2400829. doi: 10.1200/JCO.24.00829.
    >> Share

  87. YANG JC, Lee DH, Lee JS, Fan Y, et al
    Phase III KEYNOTE-789 Study of Pemetrexed and Platinum With or Without Pembrolizumab for Tyrosine Kinase Inhibitor?Resistant, EGFR-Mutant, Metastatic Nonsquamous Non-Small Cell Lung Cancer.
    J Clin Oncol. 2024 Aug 22:JCO2302747. doi: 10.1200/JCO.23.02747.
    >> Share

  88. GREER JA, Post KE, Chabria R, Aribindi S, et al
    Randomized Controlled Trial of a Nurse-Led Brief Behavioral Intervention for Dyspnea in Patients With Advanced Lung Cancer.
    J Clin Oncol. 2024 Aug 1:JCO2400048. doi: 10.1200/JCO.24.00048.
    >> Share

    July 2024
  89. YANG JJ, Zhang Y, Wu L, Hu J, et al
    Vebreltinib for Advanced Non-Small Cell Lung Cancer Harboring c-Met Exon 14 Skipping Mutation: A Multicenter, Single-Arm, Phase II KUNPENG Study.
    J Clin Oncol. 2024 Jul 26:JCO2302363. doi: 10.1200/JCO.23.02363.
    >> Share

  90. PIKE LRG, Miao E, Boe LA, Patil T, et al
    Tyrosine Kinase Inhibitors With and Without Up-Front Stereotactic Radiosurgery for Brain Metastases From EGFR and ALK Oncogene-Driven Non-Small Cell Lung Cancer (TURBO-NSCLC).
    J Clin Oncol. 2024 Jul 24:JCO2302668. doi: 10.1200/JCO.23.02668.
    >> Share

  91. DALY ME, Singh N, Ismaila N
    Management of Stage III Non-Small Cell Lung Cancer: ASCO Rapid Recommendation Update.
    J Clin Oncol. 2024 Jul 23:JCO2401324. doi: 10.1200/JCO-24-01324.
    >> Share

  92. DZIADZIUSZKO R, Rzyman W
    At the Crossroads of Local and Systemic Treatment of Operable Non-Small Cell Lung Cancer.
    J Clin Oncol. 2024 Jul 23:JCO2401099. doi: 10.1200/JCO.24.01099.
    >> Share

  93. ELKRIEF A, Montesion M, Sivakumar S, Hale C, et al
    Intratumoral Escherichia Is Associated With Improved Survival to Single-Agent Immune Checkpoint Inhibition in Patients With Advanced Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2024 Jul 22:JCO2301488. doi: 10.1200/JCO.23.01488.
    >> Share

  94. KAPADIA P, Zimolzak AJ, Upadhyay DK, Korukonda S, et al
    Development and Implementation of a Digital Quality Measure of Emergency Cancer Diagnosis.
    J Clin Oncol. 2024;42:2506-2515.
    >> Share

  95. BLAKELY CM, Urisman A, Gubens MA, Mulvey CK, et al
    Neoadjuvant Osimertinib for the Treatment of Stage I-IIIA Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer: A Phase II Multicenter Study.
    J Clin Oncol. 2024 Jul 19:JCO2400071. doi: 10.1200/JCO.24.00071.
    >> Share

  96. PEROL M
    TROP2-Directed Antibody-Drug Conjugates in Advanced Non-Small Cell Lung Cancer: A Fading Hope?
    J Clin Oncol. 2024 Jul 10:JCO2401043. doi: 10.1200/JCO.24.01043.
    >> Share

    June 2024
  97. WALIANY S, Lin JJ
    Taletrectinib: TRUST in the Continued Evolution of Treatments for ROS1 Fusion-Positive Lung Cancer.
    J Clin Oncol. 2024 Jun 28:JCO2401062. doi: 10.1200/JCO.24.01062.
    >> Share


  98. Erratum: Phase III, Randomized Study of Atezolizumab Plus Bevacizumab and Chemotherapy in Patients With EGFR- or ALK-Mutated Non-Small-Cell Lung Cancer (ATTLAS, KCSG-LU19-04).
    J Clin Oncol. 2024 Jun 17:JCO2401092. doi: 10.1200/JCO.24.01092.
    >> Share

  99. YU Y, Miao E, Pike LRG
    Improved CNS Control With the Addition of Chemotherapy to Osimertinib: A Devil's Bargain?
    J Clin Oncol. 2024;42:2107-2108.
    >> Share

  100. PARK S, Baldry R, Jung HA, Sun JM, et al
    Phase II Efficacy and Safety of 80 mg Osimertinib in Patients With Leptomeningeal Metastases Associated With Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer (BLOSSOM).
    J Clin Oncol. 2024 Jun 3:JCO2400708. doi: 10.1200/JCO.24.00708.
    >> Share

  101. PEROL M, Solomon BJ, Goto K, Park K, et al
    CNS Protective Effect of Selpercatinib in First-Line RET Fusion-Positive Advanced Non-Small Cell Lung Cancer.
    J Clin Oncol. 2024 Jun 3:JCO2400724. doi: 10.1200/JCO.24.00724.
    >> Share

  102. LI W, Xiong A, Yang N, Fan H, et al
    Efficacy and Safety of Taletrectinib in Chinese Patients With ROS1+ Non-Small Cell Lung Cancer: The Phase II TRUST-I Study.
    J Clin Oncol. 2024 Jun 1:JCO2400731. doi: 10.1200/JCO.24.00731.
    >> Share

    May 2024
  103. SOLOMON BJ, Liu G, Felip E, Mok TSK, et al
    Lorlatinib Versus Crizotinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer: 5-Year Outcomes From the Phase III CROWN Study.
    J Clin Oncol. 2024 May 31:JCO2400581. doi: 10.1200/JCO.24.00581.
    >> Share

  104. PAZ-ARES LG, Juan-Vidal O, Mountzios GS, Felip E, et al
    Sacituzumab Govitecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer: The Randomized, Open-Label Phase III EVOKE-01 Study.
    J Clin Oncol. 2024 May 31:JCO2400733. doi: 10.1200/JCO.24.00733.
    >> Share

  105. OWEN DH, Ismaila N, Freeman-Daily J, Roof L, et al
    Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2024.1.
    J Clin Oncol. 2024 May 30:JCO2400762. doi: 10.1200/JCO.24.00762.
    >> Share

  106. MO DC, Chen L, Wu Y, Huang JF, et al
    PD-L1 Expression and Its Prognostic Value in Different Tumor Specimens in Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer.
    J Clin Oncol. 2024 May 16:JCO2400230. doi: 10.1200/JCO.24.00230.
    >> Share

    April 2024
  107. SPIGEL DR, Dowlati A, Chen Y, Navarro A, et al
    RESILIENT Part 2: A Randomized, Open-Label Phase III Study of Liposomal Irinotecan Versus Topotecan in Adults With Relapsed Small Cell Lung Cancer.
    J Clin Oncol. 2024 Apr 22:JCO2302110. doi: 10.1200/JCO.23.02110.
    >> Share

  108. DAI W, Wang Y, Liao J, Wei X, et al
    Electronic Patient-Reported Outcome-Based Symptom Management Versus Usual Care After Lung Cancer Surgery: Long-Term Results of a Multicenter, Randomized, Controlled Trial.
    J Clin Oncol. 2024 Apr 4:JCO2301854. doi: 10.1200/JCO.23.01854.
    >> Share

    March 2024
  109. NEAL J, Pavlakis N, Kim SW, Goto Y, et al
    CONTACT-01: A Randomized Phase III Trial of Atezolizumab + Cabozantinib Versus Docetaxel for Metastatic Non-Small Cell Lung Cancer After a Checkpoint Inhibitor and Chemotherapy.
    J Clin Oncol. 2024 Mar 29:JCO2302166. doi: 10.1200/JCO.23.02166.
    >> Share

  110. POTTER AL, Xu NN, Senthil P, Srinivasan D, et al
    Pack-Year Smoking History: An Inadequate and Biased Measure to Determine Lung Cancer Screening Eligibility.
    J Clin Oncol. 2024 Mar 27:JCO2301780. doi: 10.1200/JCO.23.01780.
    >> Share

  111. KATHURIA H, Wiener RS
    Toward Racial Equity in Lung Cancer Screening Eligibility.
    J Clin Oncol. 2024 Mar 27:JCO2400351. doi: 10.1200/JCO.24.00351.
    >> Share

  112. RODRIGUEZ GM, Popat R, Rosas LG, Patel MI, et al
    Racial and Ethnic Disparities in Intensity of Care at the End of Life for Patients With Lung Cancer: A 13-Year Population-Based Study.
    J Clin Oncol. 2024 Mar 13:JCO2301045. doi: 10.1200/JCO.23.01045.
    >> Share

    February 2024
  113. HENICK BS, Herzberg BO, Concepcion-Crisol CP, Taylor AM, et al
    Controlled Chaos: Parsing Acquired Immunoresistance in Lung Cancer.
    J Clin Oncol. 2024 Feb 29:JCO2302339. doi: 10.1200/JCO.23.02339.
    >> Share

  114. JAIYESIMI IA, Leighl NB, Ismaila N, Alluri K, et al
    Therapy for Stage IV Non-Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, Version 2023.3.
    J Clin Oncol. 2024 Feb 28:JCO2302746. doi: 10.1200/JCO.23.02746.
    >> Share

  115. JAIYESIMI IA, Leighl NB, Ismaila N, Alluri K, et al
    Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2023.3.
    J Clin Oncol. 2024 Feb 28:JCO2302744. doi: 10.1200/JCO.23.02744.
    >> Share

  116. PIPER VALLILLO AJ, Viray H, Feldman J, Rangachari D, et al
    Management of Treatment Resistance in Patients With Advanced Epidermal Growth Factor Receptor-Mutated Lung Cancer: Personalization, Parsimony, and Partnership.
    J Clin Oncol. 2024 Feb 27:JCO2302417. doi: 10.1200/JCO.23.02417.
    >> Share

  117. REMON J, Besse B, Aix SP, Callejo A, et al
    Overall Survival From the EORTC LCG-163 APPLE Trial of Osimertinib Versus Gefitinib Followed by Osimertinib in Advanced EGFR-Mutant Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2024 Feb 7:JCO2301521. doi: 10.1200/JCO.23.01521.
    >> Share

    January 2024
  118. MOK T, Nakagawa K, Park K, Ohe Y, et al
    Nivolumab Plus Chemotherapy in Epidermal Growth Factor Receptor-Mutated Metastatic Non-Small-Cell Lung Cancer After Disease Progression on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: Final Results of CheckMate 722.
    J Clin Oncol. 2024 Jan 22:JCO2301017. doi: 10.1200/JCO.23.01017.
    >> Share

  119. STINCHCOMBE TE, Wang X, Damman B, Mentlick J, et al
    Secondary Analysis of the Rate of Second Primary Lung Cancer From Cancer and Leukemia Group B 140503 (Alliance) Trial of Lobar Versus Sublobar Resection for T1aN0 Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2024 Jan 12:JCO2301306. doi: 10.1200/JCO.23.01306.
    >> Share

  120. RICCIUTI B, Lamberti G, Puchala SR, Mahadevan NR, et al
    Genomic and Immunophenotypic Landscape of Acquired Resistance to PD-(L)1 Blockade in Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2024 Jan 11:JCO2300580. doi: 10.1200/JCO.23.00580.
    >> Share

  121. FENG YN, Xiao L, Xie GY
    Atezolizumab in Advanced Squamous Cell Carcinoma of the Penis.
    J Clin Oncol. 2024;42:242-243.
    >> Share

  122. MERIC-BERNSTAM F, Makker V, Oaknin A, Oh DY, et al
    Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial.
    J Clin Oncol. 2024;42:47-58.
    >> Share

    December 2023

  123. Erratum: Trastuzumab Deruxtecan in Patients With HER2-Mutant Metastatic Non-Small-Cell Lung Cancer: Primary Results From the Randomized, Phase II DESTINY-Lung02 Trial.
    J Clin Oncol. 2023 Dec 19:JCO2302574. doi: 10.1200/JCO.23.02574.
    >> Share

  124. DE VIS JB, Cmelak AJ, Osmundson EC
    Chemoimmunotherapy for Untreated Lung Cancer Brain Metastases: Systemic Before Local Therapy?
    J Clin Oncol. 2023 Dec 11:JCO2302151. doi: 10.1200/JCO.23.02151.
    >> Share

  125. LEHRER EJ, Trifiletti DM, Fadul CE, Brown PD, et al
    Chemoimmunotherapy for Untreated Lung Cancer Brain Metastases: A Reason for Optimism While Avoiding Overreaching Interpretations.
    J Clin Oncol. 2023 Dec 11:JCO2301876. doi: 10.1200/JCO.23.01876.
    >> Share


  126. Erratum: Phase II, Open-Label Study of Encorafenib Plus Binimetinib in Patients With BRAF(V600)-Mutant Metastatic Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2023 Dec 5:JCO2302518. doi: 10.1200/JCO.23.02518.
    >> Share

  127. JANNE PA, Planchard D, Kobayashi K, Cheng Y, et al
    CNS Efficacy of Osimertinib With or Without Chemotherapy in Epidermal Growth Factor Receptor-Mutated Advanced Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2023 Dec 2:JCO2302219. doi: 10.1200/JCO.23.02219.
    >> Share

  128. TAN DSW, Felip E, de Castro G, Solomon BJ, et al
    Canakinumab Versus Placebo in Combination With First-Line Pembrolizumab Plus Chemotherapy for Advanced Non-Small-Cell Lung Cancer: Results From the CANOPY-1 Trial.
    J Clin Oncol. 2023 Dec 1:JCO2300980. doi: 10.1200/JCO.23.00980.
    >> Share

    November 2023
  129. UPRETY D, Remon J, Peters S
    First-Line Dual Immunotherapy, a Treatment Option in First-Line Metastatic Non-Small-Cell Lung Cancer: Are We Ready to Use It?
    J Clin Oncol. 2023 Nov 30:JCO2301524. doi: 10.1200/JCO.23.01524.
    >> Share

  130. OHRI N, Jolly S, Cooper BT, Kabarriti R, et al
    Selective Personalized Radioimmunotherapy for Locally Advanced Non-Small-Cell Lung Cancer Trial.
    J Clin Oncol. 2023 Nov 21:JCO2300627. doi: 10.1200/JCO.23.00627.
    >> Share

  131. RUDIN CM, Liu SV, Soo RA, Lu S, et al
    SKYSCRAPER-02: Tiragolumab in Combination With Atezolizumab Plus Chemotherapy in Untreated Extensive-Stage Small-Cell Lung Cancer.
    J Clin Oncol. 2023 Nov 17:JCO2301363. doi: 10.1200/JCO.23.01363.
    >> Share

  132. MONK BJ, Colombo N, Tewari KS, Dubot C, et al
    First-Line Pembrolizumab + Chemotherapy Versus Placebo + Chemotherapy for Persistent, Recurrent, or Metastatic Cervical Cancer: Final Overall Survival Results of KEYNOTE-826.
    J Clin Oncol. 2023 Nov 1:JCO2300914. doi: 10.1200/JCO.23.00914.
    >> Share

    October 2023
  133. PARK S, Kim TM, Han JY, Lee GW, et al
    A Phase 3, Randomized study of atezolizumab plus bevacizumab and chemotherapy in patients with EGFR or ALK mutated in non-small cell lung cancer (ATTLAS, KCSG-LU19-04).
    J Clin Oncol. 2023 Oct 20:101200JCO2301891. doi: 10.1200/JCO.23.01891.
    >> Share

  134. HENDRIKS LEL, Remon J
    Speeding up Antibody-Drug Conjugate Development in Pretreated EGFR-Mutant Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2023 Oct 12:JCO2301830. doi: 10.1200/JCO.23.01830.
    >> Share

  135. KHURSHID H, Ismaila N, Bian J, Dabney R, et al
    Systemic Therapy for Small-Cell Lung Cancer: ASCO-Ontario Health (Cancer Care Ontario) Guideline.
    J Clin Oncol. 2023 Oct 11:JCO2301435. doi: 10.1200/JCO.23.01435.
    >> Share

  136. GARON EB, Lu S, Goto Y, De Marchi P, et al
    Canakinumab as Adjuvant Therapy in Patients With Completely Resected Non-Small-Cell Lung Cancer: Results From the CANOPY-A Double-Blind, Randomized Clinical Trial.
    J Clin Oncol. 2023 Oct 3:JCO2300910. doi: 10.1200/JCO.23.00910.
    >> Share

    September 2023

  137. Erratum: Selpercatinib in Patients With RET Fusion-Positive Non-Small-Cell Lung Cancer: Updated Safety and Efficacy From the Registrational LIBRETTO-001 Phase I/II Trial.
    J Clin Oncol. 2023 Sep 13:JCO2301849. doi: 10.1200/JCO.23.01849.
    >> Share

  138. GOTO K, Goto Y, Kubo T, Ninomiya K, et al
    Trastuzumab Deruxtecan in Patients With HER2-Mutant Metastatic Non-Small-Cell Lung Cancer: Primary Results From the Randomized, Phase II DESTINY-Lung02 Trial.
    J Clin Oncol. 2023 Sep 11:JCO2301361. doi: 10.1200/JCO.23.01361.
    >> Share

  139. HOE HJ, Solomon BJ
    Optimizing Dosing of Trastuzumab Deruxtecan in HER2-Mutant Non-Small-Cell Lung Cancer: A Reminder That More Is Not Always Better.
    J Clin Oncol. 2023 Sep 11:JCO2301768. doi: 10.1200/JCO.23.01768.
    >> Share

  140. YU HA, Goto Y, Hayashi H, Felip E, et al
    HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor-Mutated Non-Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-Based Chemotherapy.
    J Clin Oncol. 2023 Sep 10:JCO2301476. doi: 10.1200/JCO.23.01476.
    >> Share

    August 2023
  141. VERGOTE I, Van Nieuwenhuysen E, O'Cearbhaill RE, Westermann A, et al
    Tisotumab Vedotin in Combination With Carboplatin, Pembrolizumab, or Bevacizumab in Recurrent or Metastatic Cervical Cancer: Results From the innovaTV 205/GOG-3024/ENGOT-cx8 Study.
    J Clin Oncol. 2023 Aug 31:JCO2300720. doi: 10.1200/JCO.23.00720.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016